Atara Biotherapeutics, Inc. (ATRA)

NASDAQ: ATRA · IEX Real-Time Price · USD

0.679

-0.029 (-4.15%)

At close: Apr 15, 2024, 4:00 PM

0.690

+0.012 (1.72%)

After-hours: Apr 15, 2024, 7:40 PM EDT

Atara Biotherapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Net Income	-276.13	-228.3	-340.14	-306.62	-290.98	-230.7	-119.49	-79.05	-57.22	-28.01	Upgrade
Depreciation & Amortization	16.62	14.57	11.29	9.79	8.03	3.73	0.96	0.38	0.05	0.01	Upgrade
Share-Based Compensation	45.39	53.84	53.87	51.35	51.7	33.82	23.1	16.78	10.25	10.1	Upgrade
Other Operating Activities	21.14	-110.53	54.46	64.72	-4.38	13.38	7.93	1.86	9.77	1.27	Upgrade
Operating Cash Flow	-192.98	-270.43	-220.52	-180.76	-235.63	-179.77	-87.5	-60.03	-37.16	-16.63	Upgrade
Capital Expenditures	-1.2	90.57	-10.58	-4.51	-5.57	-35.93	-20.23	-3.02	-0.29	-0.05	Upgrade
Change in Investments	125.06	112.38	32.84	-116.22	66.03	-160.36	120.14	86.76	-219.64	-83.32	Upgrade
Other Investing Activities	-	-	-	-	-	-	-	-	-0.19	-	Upgrade
Investing Cash Flow	123.87	202.96	22.26	-120.73	60.46	-196.29	99.91	83.74	-220.13	-83.36	Upgrade
Share Issuance / Repurchase	2.14	21.89	98.7	422.97	188.62	340.88	19.16	0	263.43	56.46	Upgrade
Debt Issued / Paid	-0.95	30.09	-0.25	-0.39	-0.49	-0.53	0	0	0	0	Upgrade
Other Financing Activities	0.82	1.11	5.5	4.99	0.66	17.19	0.89	0.51	-4.21	13.82	Upgrade
Financing Cash Flow	2.01	53.08	103.94	427.57	188.79	357.54	20.05	0.51	259.23	70.27	Upgrade
Exchange Rate Effect	0	0	0	0	0	0	0	0	-0.09	0	Upgrade
Net Cash Flow	-67.1	-14.39	-94.32	126.09	13.62	-18.53	32.46	24.22	1.85	-29.72	Upgrade
Free Cash Flow	-194.18	-179.86	-231.1	-185.27	-241.2	-215.7	-107.73	-63.05	-37.45	-16.67	Upgrade
Free Cash Flow Margin	-2264.96%	-282.92%	-1136.19%	-	-	-	-	-	-	-	Upgrade
Free Cash Flow Per Share	-1.83	-1.76	-2.47	-2.50	-4.70	-4.92	-3.61	-2.19	-1.46	-3.34	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).